nach oben

Hepatology International

Erschienen in:

03.12.2020 | Editorial

HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?

verfasst von: Bin Zhou, Weimeng He, Jinlin Hou

Erschienen in: Hepatology International | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Excerpt

The hepatitis B virus (HBV) is a major human pathogen. The HBV genome encodes four overlapping open-reading frames (ORFs) including the S-ORF, C-ORF, P-ORF, and X-ORF. Among them, polymerase which encoded by P-ORF is the target of all approved nucleos(t)ide analogues (NAs) for antiviral therapy. NAs are generally efficient and well tolerated. However, resistance to non-first line antiviral agents is a major issue affecting long-term therapy [1]. HBx encoded by X-ORF is a nonstructural protein that serves multiple functions during the various stages of chronic HBV infection (CHB) through interaction with a number of host proteins. …

Lok AS, McMahon BJ, Brown RJ, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu DA, Prokop LJ, Wang Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology. 2016;63(1):284–306.CrossRef

Lin CL, Chien RN, Chu YD, Liang KH, Huang YH, Ke PY, Lin KH, Lin YH, Yeh CT. Hepatitis B virus X gene mutants emerge during antiviral therapy and increase cccDNA levels to compensate for replication suppression. Hepatol Int. 2020. https://doi.org/10.1007/s12072-020-10079-1.CrossRefPubMedPubMedCentral

Hughes D, Andersson DI. Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat Rev Genet. 2015;16(8):459–71.CrossRef

Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, Carrilho FJ, Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Investig. 2001;107(4):449–55.CrossRef

Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, Liaw YF, Mizokami M, Kuiken C. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46(1):254–65.CrossRef

Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol. 2007;47(4):492–8.CrossRef

Wang T, Qin Y, Zhang J, Li X, Tong S, Zhao W, Zhang J. An antiviral drug-resistant mutant of hepatitis B virus with high replication capacity in association with a large in-frame deletion in the preS1 region of viral surface gene. Virus Genes. 2020;56(6):677–86. https://doi.org/10.1007/s11262-020-01787-9.CrossRefPubMed

Zhang Y, Zhang H, Zhang J, Zhang J, Guo H. Naturally occurring core protein mutations compensate for the reduced replication fitness of a lamivudine-resistant HBV isolate. Antiviral Res. 2019;165:47–54.CrossRef

Slagle BL, Bouchard MJ. Role of HBx in hepatitis B virus persistence and its therapeutic implications. Curr Opin Virol. 2018;30:32–8.CrossRef

Titel: HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?
verfasst von: Bin Zhou
Weimeng He
Jinlin Hou
Publikationsdatum: 03.12.2020
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 6/2020
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-020-10116-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

HBx mutations emerged during antiviral therapy: a new face of a multifaceted HBV protein?

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2020

The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC

HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort

Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trial

Diagnostic performance of MRI for HCC according to contrast agent type: a systematic review and meta-analysis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin